Does Rallies show Form 4 insider transactions for APRE?

Yes. Rallies tracks APRE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is APRE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for APRE. It does not provide personalized investment advice.

APRE (Aprea Therapeutics, Inc. Common stock) Stock Analysis - Insider Trades

Aprea Therapeutics, Inc. Common stock (APRE) is a publicly traded Healthcare sector company. As of May 21, 2026, APRE trades at $0.91 with a market cap of $10.47M and a P/E ratio of -0.57. APRE moved +5.78% today. Year to date, APRE is +2.46%; over the trailing twelve months it is -48.58%. Its 52-week range spans $0.55 to $5.01. Analyst consensus is strong buy with an average price target of $4.07. Rallies surfaces APRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading APRE stock inside the company?

Recent APRE insider activity includes Gilad Oren bought 28.10K, Hamill John P. bought 5.70K, Duey Marc bought 21.46K, Hamill John P. bought 5.00K, and Gilad Oren bought 3.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

APRE Key Metrics

Key financial metrics for APRE
Metric	Value
Price	$0.91
Market Cap	$10.47M
P/E Ratio	-0.57
EPS	$-1.50
Dividend Yield	0.00%
52-Week High	$5.01
52-Week Low	$0.55
Volume	0
Avg Volume	0
Revenue (TTM)	$123.30K
Net Income	$-11.95M
Gross Margin	0.00%

Recent APRE Insider Trades

Gilad Oren bought 28.10K (~$25.01K) on Jan 30, 2026.
Hamill John P. bought 5.70K (~$5.07K) on Jan 30, 2026.
Duey Marc bought 21.46K (~$25.00K) on Dec 10, 2025.
Hamill John P. bought 5.00K (~$5.83K) on Dec 10, 2025.
Gilad Oren bought 3.00K (~$5.62K) on Apr 3, 2025.

Latest APRE News

Aprea to Unveil Early APR-1051 Safety, Efficacy Data at ASCO May 30 — Apr 21, 2026
Aprea Therapeutics Secures $30M Oversubscribed Financing to Accelerate WEE1 Inhibitor Trial — Apr 1, 2026
Aprea Secures $30M Financing, APR-1051 Shows 59.5% Tumor Reduction — Mar 30, 2026
Aprea Posts Two 50% Tumor Reductions in Phase 1 APR-1051 Trial — Mar 16, 2026
Aprea's WEE1 Inhibitor Achieves 50% Tumor Reduction, 87% CA-125 Decline at 220 mg — Feb 18, 2026

APRE Analyst Consensus

3 analysts cover APRE: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.07.

Common questions about APRE

Who is trading APRE stock inside the company?: Recent APRE insider activity includes Gilad Oren bought 28.10K, Hamill John P. bought 5.70K, Duey Marc bought 21.46K, Hamill John P. bought 5.00K, and Gilad Oren bought 3.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for APRE?: Yes. Rallies tracks APRE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is APRE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for APRE. It does not provide personalized investment advice.